Cancer Management and Research (Jun 2020)
Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data
Abstract
Christine Fischer, Rainer Hofmann, Axel Hegele Department of Urology and Pediatric Urology, University Medical Center, Marburg, GermanyCorrespondence: Christine FischerDepartment of Urology and Pediatric Urology, University Medical Center, Baldingerstraße, Marburg, GermanyEmail [email protected]/Aim: Up to 30% of all patients will present with an advanced or a metastatic stage (mUCC) at the moment of the initial diagnosis of urothelial cell carcinoma of the bladder (UCC). We investigated the numbers, the efficacy and toxicity of different chemotherapies for mUCC in daily practice and “real-life” conditions and evaluated them substance-specifically.Patients and Methods: All patients with a mUCC, who were treated between January 1, 2006 and October 31, 2016 at the Department of Urology and Pediatric Urology at University Hospital Marburg (Germany), were retrospectively analyzed. We set the focus on demographic and tumor-specific data as well as on effectiveness, therapy sequences, and drug tolerance.Results: Forty-one patients were identified. Of the 41 patients, 85.4% of the patients in first-line therapy received gemcitabine/cisplatin. A large proportion of 85.4% received a second-line therapy and 40% a third-line therapy due to progress or relapse. Median overall survival (mOS) was 18 months including all patients and increased up to 29.5 months in the cases of three therapy lines.Conclusion: Our data reveal that chemotherapy of mUCC is effective and side effects are manageable in daily clinical practice.Keywords: urothelial carcinoma, metastatic urothelial carcinoma, bladder cancer
